New hope for advanced cancer patients? early trial of SB17170 begins

NCT ID NCT05522868

Recruiting now Disease control Sponsor: SPARK Biopharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an experimental drug called SB17170 in about 50 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking for signs that the drug might slow tumor growth. Participants take SB17170 capsules daily in 21-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SB17170 (oral capsules)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Asan Medical Center
NOT_YET_RECRUITING

Seoul, South Korea
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, South Korea
Severance Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.